Tryton Medical, Inc., a Durham, N.C.-based developer of stents designed to treat bifurcation lesions, has closed a $20m Series D round of financing.
The round was led by private healthcare investor Arnerich Massena, with participation from existing investors PTV Sciences, RiverVest Venture Partners and Spray Venture Partners.
In conjunction with the funding, Russell J. Rottiers from Arnerich Massena, has joined Tryton’s board of directors.
This capital infusion will enable the company to conduct U.S. pivotal trial and drive product adoption internationally of its Tryton Side Branch Stent System, which is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation.
The system already demonstrated excellent six-month clinical and angiographic results in a first-in-man study and excellent six-month clinical results from almost 200 patients in four different registries with a rate of target lesion revascularization of less than four percent. It has received CE Mark approval in Europe and is commercially available in 21 countries throughout Europe and the Middle East.
It is not approved in the United States.